News
The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.
FEATURED STORIES
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
A recent study has highlighted the need for more stringent Phase II trial protocols on the basis that over 80% of candidate oncology treatments that go into Phase III failed to achieve OS goals.
Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Monoclonal antibodies have proven to be an important therapeutic option in the ongoing battle against COVID-19.
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
Based on BridgeBio’s current pipeline of programs, this total amount will be sufficient to carry over 30 drug development and discovery programs well into 2024.
Merck’s Keytruda (pembrolizumab) keeps expanding the indications for which it’s approved. The company announced today that the FDA had approved the anti-PD-1 therapy for adjuvant treatment of renal cell carcinoma.
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
The Richard King Mellon Foundation has awarded a $100 million gift to the University of Pittsburgh and approved a $150 million grant for Carnegie Mellon University.